Michigan HB6132 mandates the Department of Attorney General to investigate and report on insulin drug pricing for Michigan residents.
Michigan HB6132 amends the Consumer Protection Act to require the Department of Attorney General to investigate the pricing of prescription insulin drugs. The investigation will assess whether additional consumer protections are needed and gather information on insulin pricing practices, public policy recommendations, and potential legislative amendments. The attorney general must issue a public report by October 1, 2027, detailing findings and recommendations, which will be presented to the governor, relevant state officials, and legislative committees.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.